Authors:
Mantovani, G
Maccio, A
Madeddu, C
Massa, E
Mudu, MC
Mulas, C
Gramignano, G
Massidda, S
Murgia, V
Lusso, MR
Mura, L
Citation: G. Mantovani et al., Immunotherapy (recombinant interleukin 2), hormone therapy (medroxyprogesterone acetate) and antioxidant agents as combined maintenance treatment of responders to previous chemotherapy, INT J ONCOL, 18(2), 2001, pp. 383-391
Authors:
Mantovani, G
Maccio, A
Madeddu, C
Mura, L
Massa, E
Mudu, MC
Mulas, C
Lusso, MR
Gramignano, G
Piras, MB
Citation: G. Mantovani et al., Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites, J MOL MED-J, 79(7), 2001, pp. 406-414
Authors:
Campisi, C
Boccardo, F
Zilli, A
Maccio, A
Napoli, F
Citation: C. Campisi et al., Long-term results after lymphatic-venous anastomoses for the treatment of obstructive lymphedema, MICROSURG, 21(4), 2001, pp. 135-139
Authors:
Mantovani, G
Maccio, A
Mulas, C
Massa, E
Mudu, MC
Massidda, S
Massa, D
Murgia, V
Ferreli, L
Astara, G
Proto, E
Tore, G
Mura, M
Amichetti, M
Citation: G. Mantovani et al., Phase II study of induction chemotherapy followed by concomitant chemoradiotherapy in advanced head and neck cancer: Clinical outcome, toxicity and organ/function preservation, TUMORI, 87(4), 2001, pp. S43-S44
Authors:
Mantovani, G
Maccio, A
Lai, P
Massa, E
Massa, D
Mulas, C
Succu, G
Mudu, MC
Manca, G
Versace, R
Pisano, M
Citation: G. Mantovani et al., Results of a dose-intense phase 1 study of a combination chemotherapy regimen with cisplatin and epidoxorubicin including medroxyprogesterone acetateand recombinant interleukin-2 in patients with inoperable primary lung cancer, J IMMUNOTH, 23(2), 2000, pp. 267-274
Authors:
Mantovani, G
Maccio, A
Massa, E
Mulas, C
Mudu, MC
Massidda, S
Massa, D
Murgia, V
Ferreli, L
Succu, G
Astara, G
Proto, E
Tore, G
Mura, M
Maxia, G
Citation: G. Mantovani et al., Phase II study of induction chemotherapy followed by concomitant chemoradiotherapy in advanced head and neck cancer: Clinical outcome, toxicity and organ/function preservation, INT J ONCOL, 16(6), 2000, pp. 1227-1233
Authors:
Mantovani, G
Maccio, A
Mura, L
Massa, E
Mudu, MC
Mulas, C
Lusso, MR
Madeddu, C
Dessi, A
Citation: G. Mantovani et al., Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites, J MOL MED-J, 78(10), 2000, pp. 554-561
Authors:
Mantovani, G
Maccio, A
Melis, G
Mura, L
Massa, E
Mudu, MC
Citation: G. Mantovani et al., Restoration of functional defects in peripheral blood mononuclear cells isolated from cancer patients by thiol antioxidants alpha-lipoic acid and N-acetyl cysteine, INT J CANC, 86(6), 2000, pp. 842-847
Authors:
Mantovani, G
Maccio, A
Massa, E
Mulas, C
Mudu, MC
Massidda, S
Massa, D
Murgia, V
Ferreli, L
Succu, G
Astara, G
Proto, E
Tore, G
Mura, M
Maxia, G
Citation: G. Mantovani et al., Phase II study of induction chemotherapy followed by concomitant chemoradiotherapy in advanced head and neck cancer: Clinical response and organ/function preservation, ONCOL REP, 6(6), 1999, pp. 1425-1430
Authors:
Mantovani, G
Ghiani, M
Curreli, L
Maccio, A
Massa, D
Succu, G
Lai, P
Massa, E
Mudu, MC
Astara, G
Citation: G. Mantovani et al., Assessment of the efficacy of two dosages and schedules of human recombinant erythropoietin in the prevention and correction of cisplatin-induced anemia in cancer patients, ONCOL REP, 6(2), 1999, pp. 421-426
Authors:
Mantovani, G
Maccio, A
Massa, E
Lai, P
Manca, G
Mudu, C
Versace, R
Pusceddu, G
Citation: G. Mantovani et al., Relationships between Fas expression, activation molecule CD25, and functional activity of tumor-associated lymphomonocytes from neoplastic effusions, ONCOL REP, 6(1), 1999, pp. 235-239
Authors:
Mantovani, G
Curreli, L
Maccio, A
Massa, E
Massa, D
Mulas, C
Succu, G
Contu, P
Citation: G. Mantovani et al., Prevention of nausea and vomiting (N&V) in cancer patients receiving high-dose cisplatin. Assessment of the potential antiemetic activity of transdermal fentanyl (TTS-F) compared to standard antiemetic treatment in acute anddelayed N&V: First clinical report, ANTICANC R, 19(4C), 1999, pp. 3495-3502